[5]. Targeting the 5-HT3 receptor in the treatment of irritable bowel syndrome By Spiller, Robin C.From Current Opinion in Pharmacology (2011), 11(1), 68-74.
Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats.
Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats.
